The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Open accessAbstract
BACKGROUND: Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. METHODS: We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate in both groups. The primary end points were the cumulative incidence of new vertebral fracture at 24 months and the cumulative incidence of clinical fracture (nonvertebral and symptomatic vertebral fracture) at the time of the primary analysis (after clinical fractures had been confirmed in ≥330 patients). Secondary end points included the incidences of nonvertebral and hip fracture at the time of the primary analysis. Serious cardiovascular adverse events, osteonecrosis of the jaw, and atypical femoral fractures were adjudicated. RESULTS: Over a period of 24 months, a 48% lower risk of new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.001). Clinical fractures occurred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with romosozumab (P<0.001). The risk of nonvertebral fractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [8.7%] vs. 217 of 2047 patients [10.6%]; P=0.04), and the risk of hip fracture was lower by 38% (41 of 2046 patients [2.0%] vs. 66 of 2047 patients [3.2%]; P=0.02). Overall adverse events and serious adverse events were balanced between the two groups. During year 1, positively adjudicated serious cardiovascular adverse events were observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed. CONCLUSIONS: In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone. (Funded by Amgen and others; ARCH ClinicalTrials.gov number, NCT01631214 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, major cardiac events were observed in the ARCH study, while headaches, arthralgia, and injection site reactions were also observed [89,90].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As of 2021, it has reached Phase III trials, which have shown an increase in bone mineral density and a decrease in vertebral and hip fractures.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“The ARCH study showed a 48% lower risk of new vertebral fractures in the group that received romosozumab and alendronate than in the alendronate-only group [89].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationRomosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Self-citationBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,000
The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II
Lee, D. O., Hong, Y. H., Cho, M. K., Choi, Y. S., Chun, S., Chung, Y., Hong, S. H., Hwang, K. R., Kim, J., Kim, H., et al. (2024) · Journal of Menopausal Medicine · doi:10.6118/jmm.300001 · Cited by 6
Siglec-15 as a potential molecule involved in osteoclast differentiation and bone metabolism
Lu, J., Zhang, Y., Wen, H., Li, J., Chen, C., & Xiao, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38537 · Cited by 4
Cardiovascular risk assessment for osteoporosis patients considering Romosozumab
Macrae, F., Clark, E., Walsh, K., Bailey, S.-J., Roy, M., Hardcastle, S., Cockill, C., Tobias, J. H., & Faber, B. G. (2024) · Bone · doi:10.1016/j.bone.2024.117305 · Cited by 4
Characteristics of patients with very high fracture risk in a community-dwelling geriatric cohort
Rippl, M., Grupp, P., Martini, S., Müller, K. J., Tausendfreund, O., Schmidmaier, R., & Drey, M. (2024) · Bone · doi:10.1016/j.bone.2024.117366 · Cited by 4
Cardiovascular safety of osteoanabolic agents
Takeuchi, Y. (2025) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-025-01580-4 · Cited by 5
González-González, A., Álvarez-Iglesias, I., García‐Sánchez, D., Dotta, M., Reyes, R., Alfonso-Fernández, A., Bolado‐Carrancio, A., Díaz‐Rodríguez, P., Pérez‐Núñez, M. I., Rodríguez-Rey, J. C., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04165-0 · Cited by 4
Kawaguchi, H. (2025) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-025-01589-9 · Cited by 4
Tabasum, P., Umar, M., Richard, R. M., Khan, S. N., Momna, F., Shahwar, D. E., Hidayat, A., Nashwan, A. J., Sajjad, W., & Mohamed, W. I. (2025) · Cureus · doi:10.7759/cureus.80089 · Cited by 4
Park, J. Y., Chung, Y., Kim, J.-H., & Song, J. (2025) · Medicina · doi:10.3390/medicina61050805 · Cited by 4
Montoya-García, M.-J., Carbonell-Abella, C., Giner, M., Hernández-Cruz, B., Gómez‐Vaquero, C., Naranjo, A., Aviñó, R. I., Mifsut, D., Muriel, A. P. M., Mora-Fernández, J., et al. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07565-3 · Cited by 4
de Molon, R. S., Fiori, L. C., Verzola, M. H. A., Belluci, M. M., Faloni, A. P. D. S., Pereira, R. M. R., Tetradis, S., & Orrico, S. R. P. (2020) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2020.104779 · Cited by 4
Pereira, L., Meng, C., Amoedo, M. A. G., Mendes, M. T. D. S. C. P. F., Marques, M. A. M. P., Frazão, J. M., & Weigert, A. L. L. (2021) · Nefrología · doi:10.1016/j.nefro.2021.09.009 · Cited by 4
Osteoporose: Behandlung von Hochrisikopatient*innen
Schmidmaier, R. (2023) · Die Orthopädie · doi:10.1007/s00132-023-04430-1 · Cited by 4
Bone loss and new vertebral fractures during treatment with romosozumab: a case-report
Marsman, A. F., de Jongh, R. T., Teunissen, B. P., & Lems, W. F. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01367-6 · Cited by 4
Takada, J., Okimoto, N., Tsukamoto, M., Akatsuka, T., Takebayashi, T., Iba, K., & Ikeda, S. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01415-1 · Cited by 4
Advances in the Treatment of Bone-Forming Drugs Contribute to Osteoporosis Diseases
张, 方. (2020) · Advances in Clinical Medicine · doi:10.12677/acm.2020.101013 · Cited by 4
Cochran, T., Iyer, T. K., & Batur, P. (2021) · Journal of Women s Health · doi:10.1089/jwh.2021.0538 · Cited by 4
WNT signaling in skeletal homeostasis and diseases
Gori, F., & Baron, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00012-5 · Cited by 4
How to implement guidelines and models of care
Geusens, P., Appelman‐Dijkstra, N. M., Zillikens, M. C., Willems, H. C., Lems, W. F., & van den Bergh, J. P. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101759 · Cited by 4
Hong, A. R., Yang, J., Lee, J. Y., Suh, J., Lee, Y., Kim, J., & Kim, S. W. (2022) · Calcified Tissue International · doi:10.1007/s00223-022-01013-8 · Cited by 4
Liang, N., Zhang, S., Wang, S., & Ma, J. (2022) · Medicine · doi:10.1097/md.0000000000032090 · Cited by 4
Romosozumab for the treatment of postmenopausal osteoporosis
Cosman, F., & Saag, K. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00080-0 · Cited by 4
Self-citationJavaid, M. K., Mohsin, Z. A., Johansen, A., Gregson, C. L., & Pinedo‐Villanueva, R. (2022) · medRxiv · doi:10.1101/2022.01.10.22268911 · Cited by 4
Osteogenesis imperfecta: exploring an autoimmune and immunotherapy perspective
Goddard, J. F., Mehrotra, S., & Mehrotra, M. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf053 · Cited by 3
Kralles, H. L., Zhao, A. Y., Gu, A., Agarwal, A. R., & Thakkar, S. C. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01539-y · Cited by 3
Seki, K., Koyama, R., Takayama, K., Kobayashi, A., Kamimoto, A., & Hagiwara, Y. (2025) · Medicina · doi:10.3390/medicina61081348 · Cited by 3
Rui, S., Lan, Z., Wu, G., Ma, Q., Xue, D., Lin, X., & Jin, Q. (2025) · Science Progress · doi:10.1177/00368504251348587 · Cited by 3
Safety of Romosozumab in women with cancer and osteoporosis at high risk of fractures
Colle, R., Piasentier, A., Fanti, A., Gentile, L., Bodini, S., Vitale, V., Jaafar, S., Birtolo, M. F., Bertoldo, F., Mazziotti, G., et al. (2025) · Endocrine · doi:10.1007/s12020-025-04434-1 · Cited by 3
Jang, S. A., Heo, S.-J., Kwon, S., Kim, C. S., Park, S. W., & Kim, K. M. (2025) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-025-01641-8 · Cited by 3
Efficacy comparison of 6-month romosozumab plus denosumab versus 12-month romosozumab in Koreans
Lee, S., Ahn, S. H., Kim, B., Lee, S. H., Kim, H. Y., Hong, S., & Koh, J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf211 · Cited by 3
Treatment with romosozumab in patients with osteoporosis on maintenance hemodialysis
Sato, M. (2025) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-025-01651-6 · Cited by 3
Approach to the Patient - Transitions in Osteoporosis Therapy
Langdahl, B. L., Laursen, N. A., Mäkinen, V.-N., Harsløf, T., & Sølling, A. S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf614 · Cited by 3
Schietzel, S., & Huynh‐Do, U. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228145 · Cited by 3
Bai, J., Qiu, X., Shan, H., Yao, Y., Tao, L., Lin, J., Wu, C., Jiang, F., Sheng, L., Tian, B., et al. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf143 · Cited by 3
Corredor, D. C., & Pascual, L. Á. C. (2025) · Bone Reports · doi:10.1016/j.bonr.2025.101890 · Cited by 3
Chao, W.-C., Chen, Y.-H., Shih, J.-C., Cheng, B., & Ml, H. (2026) · Osteoporosis International · doi:10.1007/s00198-025-07823-4 · Cited by 3
Chen, L. K., Wang, Q., & Gu, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1732708 · Cited by 3
Zanchetta, M. B., Pernas, M. G., Jerkovich, F., Pingel, J., Schwartz, N., Erdociain, L., & Zanchetta, J. (2026) · Bone Reports · doi:10.1016/j.bonr.2026.101902 · Cited by 3
Tang, R., Wan, D., Wei, Y., Leng, C., Li, F., Wang, R., Lin, K., Ji, X., Wu, H., & Cao, S. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121544 · Cited by 3
Semeraro, A., Chialà, A., Carafa, A., Fanizzi, R., Tano, E. D., Palmisano, M., Santoro, C., Dibenedetto, F., & NAPOLI, N. (2026) · Aging Clinical and Experimental Research · doi:10.1007/s40520-026-03391-7 · Cited by 3
Wang, L., Zhang, N., Jiang, H., Tao, X., Ma, Y., Hu, Z., Zhong, C., Yang, X., Yu, S., Zhang, H., et al. (2026) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2026.101117 · Cited by 3
Osteoporose bei pneumologischen Erkrankungen
Muschitz, C., Zwick, R. H., Haschka, J., Dimai, H. P., Rauner, M., Amrein, K., Wakolbinger, R., Jaksch, P., Eber, E., & Pietschmann, P. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01896-x · Cited by 3
Drey, M., & Schmidmaier, R. (2021) · Der Internist · doi:10.1007/s00108-021-01025-w · Cited by 4
Szaraz, D., Peřina, V., Treglerová, J., Macháček, C., Zendulka, O., & Linhartová, P. B. (2024) · Frontiers in Oral Health · doi:10.3389/froh.2024.1473049 · Cited by 3
Mineta, K., Nishisho, T., Okada, M., Kamada, M., & Sairyo, K. (2024) · Bone · doi:10.1016/j.bone.2025.117392 · Cited by 3
Basic and Clinical Scientists Working Together—Do We Make the Best of Both Worlds?
Lems, W. F., Anastasilakis, A. D., Andreasen, C. M., Paccou, J., Rolvien, T., Tencerová, M., Tuckermann, J. P., Yavropoulou, M. P., & Søe, K. (2025) · Calcified Tissue International · doi:10.1007/s00223-025-01347-z · Cited by 3
Zhou, B., Hu, J., Yu, Y., Sun, L., Wang, Y., Zhang, Q., Jiang, Y., Wang, O., Xing, X., Xia, W., et al. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13831 · Cited by 3
Intravenous Administration of sRNA Nanoparticles for Treatment of Osteoporosis in Mice
Mu, X., Du, X., Han, H., Liu, F., Zheng, Z., Hao, J., Liu, L.-Z., Liu, S., Wei, Z. F., Huang, C., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060789 · Cited by 3
EndoBridge 2024: pearls and highlights
Yıldız, B. O., Armeni, E., Balodimou, C., Biondi, B., Ciudin, A., Frühbeck, G., Fuleihan, G. E., Geer, E. B., Gillard, P., Gordon, C. M., et al. (2025) · HORMONES · doi:10.1007/s42000-025-00708-5 · Cited by 3
Adami, G., Montanari, F., Fassio, A., Pollastri, F., Piccinelli, A., Benini, C., Pasetto, E., Tugnolli, M., Gatti, D., Rossini, M., et al. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf110 · Cited by 3
Liu, Y., Arora, T., Zhang, J., Sen, B., Becker, D. J., Sun, R., Yun, H., Saag, K. G., & Curtis, J. R. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07677-w · Cited by 3
Self-citationYong, A., Vandyke, K., Augustson, B. M., McCaughan, G. J. B., Talaulikar, D., Szabó, F., Prince, H. M., Ho, P. J., Quach, H., Harrison, S. J., et al. (2025) · Expert Review of Hematology · doi:10.1080/17474086.2025.2574716 · Cited by 3
Kobayashi, T., Kobayakawa, T., & Nakamura, Y. (2025) · Bone · doi:10.1016/j.bone.2025.117708 · Cited by 3
Endocrinology of Bone and Growth Disorders
Farquharson, C., Stephen, L. A., & Wong, S. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00086-4 · Cited by 3
3-PEP promotes bone regeneration by up regulating BCL-2 expression via ERK phosphorylation
Tripathi, A., Awasthi, P., Rawat, K. S., Dwivedi, A. P., Singh, K. B., Sharma, K., Prakash, R., Singh, D. R., & Goel, A. (2022) · Journal of Endocrinology · doi:10.1530/joe-21-0439 · Cited by 3
Liu, Y., Arora, T., Zhang, J., Sodhi, S. K., Xie, F., & Curtis, J. R. (2023) · Bone · doi:10.1016/j.bone.2023.116954 · Cited by 3
Utilization of Romosozumab in Primary Care
Yang, S. H., Mittal, N., Bell, A. L., & Bell, C. E. (2023) · Journal of Pharmacy Technology · doi:10.1177/87551225231220221 · Cited by 3
Kobayakawa, T., Kanayama, Y., Hirano, Y., & Nakamura, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-73398-5 · Cited by 3
Glucocorticoid-induced osteoporosis in systemic lupus erythematosus
Phang, K. F., Cho, J., Lee, W., & Mak, A. (2018) · Rheumatology Practice and Research · doi:10.1177/2059902118802510 · Cited by 3
Crump, L. H., Benfield, M. J., Ramey, C., Arcara, A., Yang, S., Brown, J., Mospan, G. A., & Mospan, C. M. (2019) · The Nurse Practitioner · doi:10.1097/01.npr.0000605508.04187.b2 · Cited by 3
Rao, M., & Awasthi, M. (2020) · AIMS Medical Science · doi:10.3934/medsci.2020015 · Cited by 3
Karimifar, M., Botlani, N., & Salari, A. (2020) · Journal of Preventive Epidemiology · doi:10.34172/jpe.2020.16 · Cited by 3
Altaf, A., Alkefai, N. H. A., Panda, B. P., Usmani, Z., Amin, S., & Mir, S. R. (2022) · Fermentation · doi:10.3390/fermentation8040182 · Cited by 3
Brandi, M. L., & Medio, L. D. (2020) · Endocrinology · doi:10.1007/978-3-030-14782-2_19 · Cited by 3
Self-citationDrug discovery in spinal cord injury-induced osteoporosis: a text mining-based study
Wang, C., Xu, Y., Han, L., Wu, W., & Lu, X. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-6900 · Cited by 3
Bliuc, D., Tran, T. S., Chen, W., Alarkawi, D., Alajlouni, D. A., Blyth, F., MARCH, L. M., & Blank, R. D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac669 · Cited by 3
Fracture distribution in postmenopausal women: a FRISBEE sub-study
Mugisha, A., Body, J.-J., Iconaru, L., Baleanu, F., Charles, A., Rozenberg, S., Mureille, S., Bergmann, P., & Benoit, F. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01191-w · Cited by 3
Prevention of osteoporotic fracture: from skeletal and non-skeletal perspectives
Wang, X., Yang, W., & Qin, L. (2022) · Frigid Zone Medicine · doi:10.2478/fzm-2022-0029 · Cited by 3
Patients with osteoporosis: children of a lesser god
Adami, G., Tsourdi, E. A., Rossini, M., Funck‐Brentano, T., & Chapurlat, R. D. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002973 · Cited by 3
HU, G. (2022) · FARMACIA · doi:10.31925/farmacia.2022.5.21 · Cited by 3
Determining patient preferences for the medical management of osteoporosis using conjoint analysis
Liu, X., Makaroff, K. E., Almario, C. V., Khalil, C., Choi, S. Y., Curtis, J. R., & Spiegel, B. M. R. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06882-9 · Cited by 3
Update der S3-Leitlinie Diagnostik, Prophylaxe und Therapie der Osteoporose
Drey, M., Otto, S., Thomasius, F. E., & Schmidmaier, R. (2023) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-023-02245-5 · Cited by 3
Yadalam, P. K., Anegundi, R. V., Ramadoss, R., Shrivastava, D., Alruwaili, A. M., Faheemuddin, M., & Srivastava, K. C. (2024) · European Journal of General Dentistry · doi:10.1055/s-0043-1777841 · Cited by 3
Update on Therapies and Treatments in Women’s Health
Prifti, C. A., Casas, R. S., Merriam, S. B., Yecies, E. B., & Walsh, J. M. E. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.007 · Cited by 3
Pereira, R. C., Noche, K. J., Gales, B., Chen, Z., Salusky, I. B., & Albrecht, L. V. (2024) · Children · doi:10.3390/children11070820 · Cited by 3
A Review on the Recent Trend in Osteoporosis Highly Cited Papers
Mansourzadeh, M. J., Panahi, N., Fahimfar, N., Moheimani, H., Aalaa, M., Sanjari, M., Khalagi, K., Hajivalizadeh, F., Ostovar, A., & Soltani, A. (2022) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-022-09285-2 · Cited by 3
Making sure the first osteoporotic fracture is also the last
Breuil, V. (2019) · Joint Bone Spine · doi:10.1016/j.jbspin.2019.06.009 · Cited by 3
Lifelong genetically lowered sclerostin and risk of cardiovascular diseasePreprint
Bovijn, J., Krebs, K., Chen, C., Boxall, R., Censin, J. C., Ferreira, T. D. G. M., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/531004 · Cited by 3
Fracture risk assessment in nursing homes
Harvey, N. C., & Cooper, C. C. (2020) · European Geriatric Medicine · doi:10.1007/s41999-020-00384-1 · Cited by 3
Romosozumab and cardiovascular safety—should we learn lessons from pioglitazone?
Jacob, J. J., & Paul, T. V. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06271-0 · Cited by 3
Kawaguchi, H. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae347 · Cited by 3
Changes in Testing and Treatment Methods in Osteoporosis Care
Nagai, T., Ishikawa, K., Tsuchiya, K., Tani, S., Dodo, Y., Oshita, Y., Sakamoto, K., Kawate, N., & Kudo, Y. (2024) · Journal of Osteoporosis · doi:10.1155/2024/9629891 · Cited by 2
Nikitsina, M., Quiroga-Colina, P., & Castañeda, S. (2024) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2024.06.011 · Cited by 2
Die aktuelle Leitlinie für Osteoporose
Drey, M., Otto, S., Thomasius, F. E., & Schmidmaier, R. (2024) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-024-4207-6 · Cited by 2
Wong, P. K. K., Roberts, A. G. K., Ho, T., Fraser, S., Thompson, J., Williamson, J., & Hay, E. (2024) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.15421 · Cited by 2
Huang, X., Li, C., Lau, Y., Lin, Z., OuYang, C., & Zheng, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-88137-7 · Cited by 2
Atherosclerosis, vascular calcification and osteoporosis
Valero, C., & Macías, J. G. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.02.001 · Cited by 2
Smakaj, A., Tarantino, U., Iundusi, R., Chiavoghilefu, A., Abbondante, L., Salvati, C., Greggi, C., & Gasbarra, E. (2025) · Diseases · doi:10.3390/diseases13050148 · Cited by 2
Diagnostik und Therapie der Osteoporose im Jahr 2025
Klemm, P., Schulz, N., Lange, U., & Buehring, B. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01884-7 · Cited by 2
Wung, C.-H., Liu, H., Tsai, T., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1569744 · Cited by 2
Risk factors and reasons for romosozumab nonadherence in a case-control study
Tsai, T.-C., Yen, Y.-S., Lin, C.-H., Cheng, Y.-C., Ding, Y.-S., Chiang, C.-H., & Wu, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-04595-z · Cited by 2
Ko, Y., Song, B. G., Shin, H., Park, Y., Park, J., Park, M. K., Lee, Y. B., Yu, S. J., Sinn, D. H., Kim, Y. J., et al. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07602-1 · Cited by 2
Mesinovic, J., Ryan, J. R., Ng, C., Zengin, A., Ebeling, P. R., & Scott, D. A. H. (2025) · Bone · doi:10.1016/j.bone.2025.117656 · Cited by 2
Keaveny, T. M., Oates, M. K., Betah, D., Shi, Y., Timoshanko, J., Lee, D. C., Bydon, M., Krohn, K., & Ishikawa, K. (2025) · The Spine Journal · doi:10.1016/j.spinee.2025.10.032 · Cited by 2
Research Status and Hot Spot Visualization Analysis of Osteoporosis from 2014 to 2025
Huang, Y., Wang, F., Lian, K., Li, L., & Wang, Z. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s541592 · Cited by 2
Wang, Z., Mei, Y., Shen, L., Gu, J., Ren, N., Wang, Y., Zhang, Z., & Wang, C. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s533224 · Cited by 2
Geusens, P., Hul, W. V., van den Bergh, J. P., & Lems, W. F. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2594642 · Cited by 2
Câmara, L. C., Ferreira, M. H. L., & Junior, N. C. (2025) · Cureus · doi:10.7759/cureus.98114 · Cited by 2
Yoshiyama, T., Fukasawa, T., Masuda, S., Matsuda, S., & Kawakami, K. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01646-w · Cited by 2
Lu, K.-H., Wang, S., & Yang, S.-F. (2026) · Biology of Sex Differences · doi:10.1186/s13293-025-00817-1 · Cited by 2
Metadata
- Authors
- Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A.
- Affiliations
- Inserm (FR)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-10-12
- Volume
- 377
- Issue
- 15
- Pages
- 1417-1427
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2754720807
- Cited by
- 1,544
- References
- 31
- Citations by year
- 2026: 204 · 2025: 216 · 2024: 210 · 2023: 148 · 2022: 179 · 2021: 172 · 2020: 185 · 2019: 114 · 2018: 94 · 2017: 19
- FWCI
- 123.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Teva Pharmaceutical Industries
- Radius Health
- Medac
- Chugai Pharmaceutical
- Amgen Canada
- UCB Pharma
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- romosozumab, alendronate, osteoporosis, fracture prevention, sclerostin inhibition, postmenopausal women, vertebral fractures, hip fracture, non-vertebral fractures, bisphosphonates, cardiovascular adverse events, osteonecrosis of the jaw, atypical femoral fractures, bone formation, bone resorption, fragility fractures, open-label extension
- MeSH terms
- Aged, Antibodies, Monoclonal, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Least-Squares Analysis, Spinal Fractures, Bone Remodeling, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
